Objectives: Our aim was to conduct a comparative study in a large cohort of myopathic patients carrying LMNA gene mutations to evaluate clinical and molecular features associated with different phenotypes.
muscular dystrophy 2 (EDMD2), and a form of congenital muscular dystrophy (MDCL). Most previously reported studies focused on a single phenotype [15] [16] [17] and less on larger cohorts of patients with LMNA mutations characterized by different muscular phenotypes. 2, 18, 19 We aimed to conduct a study on a large cohort of patients with LMNA mutations and muscular disorders as well as familial cases without musculoskeletal involvement to compare clinical and molecular features associated with each phenotype.
METHODS Patients. We included 78 patients with LMNA mutations and obvious signs of skeletal muscle involvement from the databases of 11 tertiary care neuromuscular centers in Italy. Patients were classified as MDCL if they had hypotonia or muscle weakness presenting within the first year of life or delayed motor milestones (DMM). Patients with later onset were diagnosed according to the distribution of muscle weakness as 20 LGMD1B in case of prominent limb-girdle weakness, 15 and EDMD2 in case of scapulo-humero-peroneal weakness. Proximal lower limb weakness was admitted in EDMD2 as previously reported, 16, 21 but only if it was not prominent on other regions. We diagnosed as atypical those patients whose skeletal muscle involvement was not consistent with the aforementioned categories. We also included 30 family members without skeletal muscle involvement, but carrying LMNA mutations. We excluded 38 patients with LMNA mutation, sporadic or without any familial cases with muscle involvement, affected by different phenotypes (i.e., neuropathic, cardiopathic, progeroid, lipodystrophic, or asymptomatic phenotype). Clinical, histologic, and cardiologic data and genomic mutations were retrospectively evaluated. Cardiologic follow-up was performed at least on an annual basis, through standard 12-lead ECG, echocardiogram, and, if indicated, other investigations. For purposes of this study, we did not consider isolated ectopic supraventricular or ventricular heart beats to be suggestive of arrhythmia. Familial cases with mutations, but without muscle involvement, underwent neurologic and cardiologic evaluation at least once.
Standard protocol approvals, registrations, and patient consents. The local ethics committees approved this study. All patients, parents/guardians, or healthy individuals provided written informed consent for genetic analysis and use of their anonymized clinical data at the time of their first visit at the individual centers.
Genetics. We confirmed laminopathy diagnosis by molecular analysis in all patients and confirmed pathogenicity of novel mutations by screening at least 100 unrelated healthy Italian individuals as controls.
Statistical and bioinformatics analysis. We used t test or
Mann-Whitney U test as appropriate for analysis of quantitative variables between 2 groups and analysis of variance or KruskalWallis test to compare more than 2 groups; post hoc tests were adjusted with Bonferroni correction. To evaluate the association between categorical variables, we conducted Fisher exact test or Pearson x 2 test in case of 2 or more categories, respectively. We used SPSS software version 20 (IBM Corp., Armonk, NY) (significance level 5 0.05).
RESULTS
Of the 78 myopathic patients enrolled in the study, 37 (47.4%) had LGMD1B, 18 (23.1%) MDCL, 17 (21.8%) EDMD2, and 6 (7.7%) an atypical myopathic phenotype. The mean follow-up period was 7.5 6 7.0 years (range 0.6-40 years). Table 1  shows clinical features of myopathic patients and the  30 familial cases without muscle involvement, and  table 2 shows associations between clinical features  and muscle phenotypes. Clinical features at onset. The mean age at onset of muscle weakness was 12.2 6 9.2 years for patients with EDMD2, 27.5 6 19.1 years for patients with LGMD1B, and 29 6 19.2 years for atypical cases (analysis of variance, p 5 0.018). Post hoc analysis revealed a difference in the age of muscle weakness onset between EDMD2 and LGMD1B patients (p 5 0.018). Lower limb weakness and walking difficulty, observed in 56 patients, were the most common presentations. Four patients presented with isolated upper limb weakness. The mean age at onset for patients with MDCL was 0.9 6 0.6 years. Six patients with MDCL presented at birth or in the first months of life with hypotonia, in one case associated with arthrogryposis (patient 64); 8 patients with MDCL presented with DMM, and 4 (patients 46, 82, 86, and 108) with isolated dropped head syndrome (DHS), which developed after normal acquisition of head control. Contractures preceded muscle weakness in 20 of the 78 patients (25.6%).
Distribution of weakness. Six patients presented with an atypical phenotype characterized by isolated humeral, peroneal, or quadriceps weakness, in some cases with contractures (table 1) . The clinical phenotype of the remaining 72 patients was mainly characterized by predominant weakness of scapular and/or pelvic muscles in 44 of 72 patients (61.1%), 8 of whom also showing marked axial involvement. Thirty patients (38.5%) had scapular winging, mostly those with EDMD2. Patient 79, presenting with DMM, had only difficulty running during the follow-up period. We observed eyelid ptosis or ocular paresis in 6 patients (7.7%), of whom 3 had MDCL; 9 patients (11.5%) had facial weakness, mostly those with EDMD2 and MDCL. None of the patients underwent gastrostomy.
Motor function abilities during follow-up. Nine (11.5%) of the 78 patients were wheelchair-bound: 3 patients with MDCL were never able to walk or stand unsupported; 2 others lost the ability to walk at the age of 14 years; 2 patients with EDMD2 lost ambulation in the fifth decade of life; and 2 with LGMD1B became unable to walk in the third and fourth decade of life, respectively. One patient with MDCL and one with LGMD1B required a wheelchair Continued to move about outdoors, and one with MDCL and one with LGMD1B required support to walk. Among patients who walked independently, 45 of 65 patients (69.2%) had a predominant waddling gait, and 16 of 65 walked with a normal gait, although most had difficulty in running, climbing stairs, getting up from the floor, or walking on heels. Two patients with EDMD2 and one with MDCL were exclusively toe-walkers, and one patient with EDMD2 had only a steppage gait.
Cardiac features. Fifty-four (69.2%) of the 78 patients had cardiac involvement; the mean age overall at detection was 31.8 6 15.1 years, significantly later in patients with LGMD1B (37.9 6 15.4 years) than in those with EDMD2 (25.6 6 9 years; post hoc p 5 0.038) and MDCL (20 6 13 years; post hoc p 5 0.004). Eleven patients (9 LGMD1B and 2 atypical) had heart disease presentation before onset of muscle weakness (range 2-25 years). In the remaining 43 patients, the mean period between onset of muscle weakness and cardiac presentation ranged from 0 to 43.5 years. Patients without heart involvement had a mean age at the last control follow-up of 25.1 6 22 years (range 3-68 years).
The most frequently observed arrhythmias were atrioventricular or intraventricular conduction defects (n 5 36), atrial fibrillation (n 5 34), and supraventricular or ventricular tachyarrhythmias (n 5 21). Seventy-three patients (93.6%) underwent at least of respiratory complications; patient 95 had cardiac sudden death without any previous sign of heart involvement at 68 years of age, and patient 96 at 28 years of age with only nonspecific ECG changes. Three patients who died of arrhythmias were implanted of a PM only. b Heart transplant.
one echocardiogram during the observation period: 33 patients (45.2%) had normal results; 35 patients (47.9%) showed dilated cardiomyopathy with bilateral atrial dilation and ventricular systolic dysfunction; 1 patient (1.4%) had hypertrophic cardiomyopathy; and 4 (5.6%) had hypokinetic or dyssynergic cardiomyopathy. Forty-one (52.6%) of 78 patients underwent implantation of an implantable cardioverter defibrillator (ICD) (n 5 35) or pacemaker (PM) (n 5 6), at a mean age of 42.5 6 11.8 years. Age at ICD or PM implantation was significantly later for patients with LGMD1B (48.4 6 8.3 years) than patients with MDCL (30.1 6 13.7 years; post hoc p 5 0.001). Eight patients had heart transplantation at a mean age of 41.7 6 12.7 years; 7 of those patients had previous ICD.
Orthopedic complications. We observed contractures in 59 patients (75.6%), mainly localized to the ankle (n 5 49), cervical paraspinal muscles (n 5 32), and elbow (n 5 30). Six patients (7.7%) underwent ankle tenotomy at an age ranging from 4 to 18 years, experiencing improved ambulation. Twenty-one (26.9%) of the 78 patients had scoliosis and 36 (46.2%) spinal rigidity, 15 (41.7%) of whom also had scoliosis. None underwent corrective scoliosis surgery.
Histopathologic features. Muscle biopsies were available for 51 of 78 patients (65.4%). We observed a myopathic pattern, mainly characterized by fiber size variation and relatively hypotrophic type 1 fibers in 16 of the 51 (31.4%) biopsy samples, mild to moderate dystrophic features in 20 (39.2%) patient samples, aspecific and minimal changes in 5 (9.8%), and both myopathic and neurogenic features in 7 (13.7%). Three patients (5.9%) with LGMD1B had myofibrillar changes with desmin accumulation.
Familial cases without muscle involvement. The mean age at last follow-up of the 30 familial cases with LMNA mutations, but without skeletal muscle involvement, was 43.4 6 13.9 years (range 19-67 years). Twenty of the 30 (66.7%) had cardiac involvement, with a mean age at presentation of 33.2 6 12 years; 7 of the 20 patients (35%) underwent ICD implantation at a mean age of 44.4 6 7.7 years. None had heart transplantation or died in Table 2 Associations between clinical features and muscle phenotypes
LGMD1B the follow-up period. The remaining 10 patients (33.3%) had normal neurologic examination and heart investigations.
Five of 30 familial cases had mild creatine kinase elevation (range 234-429 IU/L). Eight of the 30 patients (26.7%) had cervical contractures. Nineteen patients underwent muscle imaging (17 patients, MRI; 2 patients, CT scan) and all had abnormal results, ranging from minimal posterior leg abnormalities to marked thigh and leg involvement, despite no evident muscle weakness. The only differences in heart involvement or its complications when comparing the 78 myopathic patients and the 30 familial members without muscle involvement were that 41 of the 78 (52.6%) myopathic patients had an ICD or PM compared with 7 of 30 (23.3%) familial cases (p 5 0.005), and death during the observation period occurred in 10 of 78 (12.8%) myopathic patients and none of the familial cases (p 5 0.032).
Clinical course. During the observation period, 10 patients (12.8%) died at a mean age of 36.2 6 24.8 years (range 7-68 years). Of the remaining 68 patients, 56 (82.4%) presented a slowly progressive clinical course, whereas 9 (13.2%) were stable or even mildly improved, after initial worsening. Two patients with EDMD2 and one with MDCL had a relatively rapid progression.
Among the 4 patients with MDCL presenting with isolated DHS, 3 progressed to LGMD1B, one of them with improvement of axial weakness. The remaining 14 patients with MDCL developed EDMD2 in 4 cases, LGMD1B in 6, diffuse and severe weakness in 1, atypical phenotypes in 2, and 1 patient (number 79) did not show any muscle weakness, but had running difficulty.
Six patients (7.7%) had a stroke likely of cardioembolic origin at an age ranging from 41 to 59 years. Of note, all of them had atrial fibrillation. Six of 78 patients (7.7%) required assisted ventilation at an age ranging from 17 to 50 years.
Data from EMG and nerve conduction studies were available for 50 of 78 patients (64.1%); 4 of 50 patients (8%) developed clinical and neurophysiologic neuropathy, mainly axonal.
LMNA gene analysis. We found 48 different LMNA mutations, including 7 novel, 35 missense, 7 frameshift, 3 splice, 2 in-frame, and 1 nonsense mutation. The majority of these mutations involved exon 6, followed by exons 1, 4, and 9 (figure). Missense mutations were mostly found in patients with EDMD2 and MDCL; a similar proportion of missense and frameshift mutations were associated with patients with LGMD1B (see table 3 ). Associations between myopathic phenotypes, as well as muscle and heart involvement with the type of mutations and the lamin A/C protein domains are presented in tables 3 and 4, respectively. Effects of the novel missense mutations are described in table e-1 on the Neurology ® Web site at Neurology.org. DISCUSSION Our study includes clinical details on a very large cohort of LMNA myopathic patients, allowing statistical analysis for evaluation of the main features of the different muscle phenotypes. Almost half of the patients had LGMD phenotype, which is by far the most frequent one; this result is in agreement with a previous Italian study including 27 patients, 19 whereas the 13 patients in an Australian study mostly had EDMD2 or MDCL. 18 A review of data reported on the Universal Mutation Database (LMNA page) did not provide clinical details of the different myopathic forms.
2 EDMD2 frequency may be underestimated in the present study because in cases with diffuse involvement, it was sometimes difficult to ascertain from the clinical history whether the phenotype was initially scapuloperoneal with subsequent involvement of the lower limb proximal muscles. However, we observed that prevalent pelvic muscle weakness was a distinguishing feature between EDMD2 and LGMD1B, as already suggested. 20 Contractures, traditionally associated with EDMD2 and more rarely with LGMD1B, 15, 16, 19 were observed in 24 of 37 patients with LGMD1B; in 13 patients, contractures were localized at multiple sites and in 10 developed before obvious clinical signs of muscle weakness. In contrast, one patient with EDMD2 had no contractures and one had only ankle contractures. Patients with MDCL displayed a pattern of contractures similar to those with EDMD2; these data suggest an important overlap between LMNA-related myopathies, possibly representing a continuum in the clinical spectrum. 8 The frequency of elbow contractures was significantly different between specific muscle phenotypes, occurring more commonly in patients with EDMD2 or MDCL. This observation should be kept in mind for differential diagnosis between severe cases of EDMD2 and LGMD1B.
About half of the patients presented in the first decade of life, indicating that LMNA-related myopathies should be considered in the differential diagnosis of early-onset myopathies, in particular for early detection and management of cardiologic aspects.
In the present study, the largest series reported to date, the MDCL phenotype was present in almost 25% of the cohort. This high frequency is probably attributable to our inclusion criteria because we also classified as congenital muscular dystrophies infants with DMM, in whom signs of weakness presented before achieving independent walking, in agreement with recently published criteria. 22 Our results confirm that, in infants who had already achieved head control, DHS is more common than the severe MDCL early-onset phenotype. 17 All but one patient with DHS progressed to a more diffuse pattern of weakness; the one patient continued with exclusively axial weakness. Of patients in our sample with MDCL, half progressed to LGMD1B and only 5 to EDMD2; these results are in contrast to a previous study reporting prevalent progression to EDMD2. 17 Seventy percent of patients in our sample had cardiac involvement, similar to previous reports, [23] [24] [25] and most presented before the age of 50 years; 20% presented in the first 2 decades of life. Cardiac involvement occurred significantly earlier in patients with MDCL and EDMD2 than those with LGMD1B, also reflecting younger age at onset of muscle weakness. 19 Age at ICD or PM implantation differed significantly between patients with MDCL and LGMD1B, but not between those with EDMD2 and LGMD1B, suggesting a slower progression of cardiac conduction defects in patients with EDMD2 than in LGMD1B. Despite varying myopathic phenotypes, patients shared similar cardiac impairments, confirming a continuum in the spectrum of clinical presentation. In addition, we observed no difference between the 30 familial cases without muscle involvement and the 78 myopathic patients, except for heart transplantation, ICD or PM implantation, and death, which occurred more frequently in myopathic patients, probably because of longer and more careful cardiologic follow-up. In addition, muscle damage, and consequently motor disability, may somehow contribute to the progression of heart disease.
Results from this large series of patients with LMNA mutations and varying phenotypes confirm that even in the presence of muscle weakness, the natural history of LMNA-related myopathies appears to be dominated by cardiac involvement. Indeed, none of the patients in this cohort underwent gastrostomy or surgery for scoliosis and only 6 of 78 patients needed assisted ventilation at any time during the study Table 3 Associations among type of mutations, specific muscle phenotypes, muscle, and heart involvement Frameshift LGMD1B 5 limb-girdle muscular dystrophy 1B; MDCL 5 congenital muscular dystrophy. Data are n (%). The p value was estimated using x 2 test. a All patients with muscle involvement (n 5 78) were included in the analysis. b Data considered more relevant on the basis of expected frequencies. c All patients with muscle involvement and familial cases without muscle involvement (n 5 108) were included in the analysis. Table 4 Associations between lamin A/C domains and specific muscle phenotypes, muscle, and heart involvement LGMD1B 5 limb-girdle muscular dystrophy 1B; MDCL 5 congenital muscular dystrophy. Data are n (%). The p value was estimated using x 2 test. a All patients with muscle involvement (n 5 78) were included in the analysis. b Data considered more relevant on the basis of expected frequencies. c All patients with muscle involvement and familial cases without muscle involvement (n 5 108) were included in the analysis.
period. Loss of ambulation or need of support to walk occurred in 15% of patients in this study. To this purpose, apart from 3 patients with MDCL who never were able to walk, 6 patients became wheelchairbound after a mean period of 23.2 6 10.2 years (range 13-36 years) from disease onset, revealing a relatively slow progression of muscle weakness. Approximately 13% of study patients died during the study period, mainly due to heart involvement; among them were 4 patients with MDCL, all deceased before the age of 21.
Progression of functional motor limitation was usually slow; major events during the clinical course were mainly related to heart involvement. Therefore, we suggest periodic cardiologic evaluation in patients with LMNA mutations because of the possible long latency between muscle and heart involvement. It is worth pointing out that in our cohort about one-fifth of patients presented heart disease after at least 20 years from myopathy onset. However, heart disease preceded muscle involvement in 11 of 78 patients, suggesting that LMNA molecular analysis should be considered in the differential diagnosis in young patients with heart disease of unknown origin. Although ICD implantation should be considered in patients with arrhythmias, its use in younger patients, in particular patients with MDCL, 23, 24 remains an open question.
We observed missense mutations more frequently in patients with EDMD2 and MDCL, and frameshift mutations in patients with LGMD1B. In turn, frameshift mutations were significantly more frequent in patients with heart involvement, whereas missense mutations were present in patients without cardiac involvement, as already suggested by a previous smaller Italian study. 19 In patients with EDMD2 and LGMD1B, gene variants were mainly distributed in immunoglobulin-like (exons 7-10) and coil 2B (exon 6) regions, respectively, both crucial for interactions with several inner nuclear membrane proteins and lamin dimerization. 19, 26, 27 However, variants associated with the MDCL cluster in the N-terminal and the first part of the rod domains (exon 1, exons 4 and 5), while mutations in the tail domain are not significantly associated with heart involvement, confirming that myocardium might be more sensitive to alterations in the N-terminal portion of lamin A/C than skeletal muscle. 28 Extensive inter-and intrafamilial variability and severity were confirmed in our patients, 7-14 although only 5 of 18 families displayed differing myopathic phenotypes within a family. Further studies are needed to clearly elucidate the factors that influence clinical expression in LMNA-related myopathies. For instance, a modifier locus for muscle involvement in EDMD2 was recently identified on chromosome 2, in a region including DES and MYL1 genes, 29 and other authors hypothesized that there are additional possible modifiers of clinical expression of laminopathy. 
